Am J Transplant, Volume 16, Suppl 3 Archives - Page 154 of 180 - ATC Abstracts

2016 American Transplant Congress
Human Epineural Allograft Conduits Supported with Mesenchymal Stem Cells Enhance Peripheral Nerve Regeneration: A Preliminary Report.
M. Siemionow, M. Strojny, W. Malewski, J. Cwykiel, M. Cyran.
Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL.
PURPOSE: Due to the limitations of current surgical methods of long nerve defect repair, new therapeutic approaches are needed to enhance nerve regeneration. Nerve allografts…
2016 American Transplant Congress
Tofacitinib Delivered by Solid Lipid Nanoparticles Inhibits Dendritic Cell Maturation and Their Allostimulatory Capacity.
J. Budihardjo,¹ M. Iglesias,¹ J. Walch,¹ X. Calderon-Colon,² W. Lee,¹ G. Brandacher,¹ J. Patrone,² G. Raimondi.¹
¹Plastic Surgery, Johns Hopkins Medical Institutions, Baltimore, MD; ²Applied Physics Laboratory, Johns Hopkins University, Laurel, MD.
BackgroundComplications caused by long-term immunosuppression remain a major concern for transplant patients. To optimize controlled and accurate dosing, we investigated an innovative drug delivery method…
2016 American Transplant Congress
Novel Nuclear Factor-κB Activation Inhibitor, Dehydroxymethylepoxyquinomicin, Prevents the Development of Chronic Cyclosporine Nephropathy in Rats.
S. Morita,¹ K. Shinoda,¹ S. Tamaki,¹ H. Kono,² Y. Kanno,³ K. Umezawa,⁴ K. Nakagawa,² M. Oya.¹
¹Urology, Keio University School of Medicine, Tokyo, Japan; ²Urology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Chiba, Japan; ³Nephrology, Tokyo Medical University, Tokyo, Japan; ⁴Molecular Target Medicine Screening, Aichi Medical University, Nagakute, Aichi, Japan.
Purpose:The nephrotoxicity of the calcineurin inhibitors including cyclosporine is a major problem in the kidney transplantation. We investigated the effect of a novel nuclear factor-κB…
2016 American Transplant Congress
Three Months of Weekly Rifapentine Plus Isoniazid for Latent Tuberculosis Treatment in Solid Organ Transplant Candidates.
B. Knoll,¹ R. Nog,¹ Y. Wu,² A. Dhand.¹
¹Medicine, Division of Infectious Diseases, Westchester Medical Center, Valhalla, NY; ²Division of Transplant and Hepatobiliary Surgery, Westchester Medical Center, Valhalla, NY.
Purpose: Although isoniazid 300 mg daily for 9 months is the recommended regimen for latent tuberculosis infection (LTBI) in solid organ transplant (SOT) candidates, its…
2016 American Transplant Congress
Clinical Risk Factors for the Recurrence of Clostridium difficile Infection (CDI) in Solid Organ Transplant Recipients (SOTR).
Y. Natori, M. Shiotsuka, L. Oen, E. Renner, L. Singer, J. Kim, H. Ross, D. Kumar, C. Rotstein, A. Humar, S. Husain.
Multi-Organ Transplant, University Health Network, Toronto, ON, Canada.
Introduction:CDI is a common complication in SOTR. Recurrence may occur after treatment of the initial episode. However, the clinical risk factors of the recurrence of…
2016 American Transplant Congress
First Experience with Obinutuzumab (Type II Anti-CD20) in Patients with Treatment-Resistant Glomerular Diseases and Antibody-Mediated Rejection.
J. Choi, S. Jordan, A. Vo.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: There is extensive experience with rituximab (RTX,Type I anti-CD20) for desensitization (DES) and treatment of ABMR. There is also a comparable experience in treatment…
2016 American Transplant Congress
Belatacept Conversion in Adult Kidney Transplant Recipients for Cause: A Single Center Observational Cohort.
M. Savic,¹ M. Cruz,² A. Rossi,¹ J. Vella.¹
¹Maine Transplant Program, Maine Medical Center, Portland, ME; ²University of Connecticut, Storrs, CT.
Background: Calcineurin inhibition (CNI) is the single most effective strategy to prevent allograft rejection however tolerability is limited by toxicity. To date, alternate strategies have…
2016 American Transplant Congress
Donor-Specific Antibodies in a Single-Center Pediatric Kidney Transplant Population – Incidence and Risk Factors.
M. Bock,¹ L. Starkey,¹ C. Buchanan,² E. Steinberg,² A. Sikora,² K. McKinnon,² M. Wachs,² J. Goebel.¹
¹Transplant Surgery, Children's Hospital Colorado, Aurora, CO; ²Pediatric Nephrology, Children's Hospital Colorado, Aurora, CO.
In mid-2015, we implemented donor-specific antibody (DSA) monitoring in our pediatric kidney transplant recipient (pKTR) population as recommended (Transplantation 2013;95:19-). We now cross-sectionally analyzed our…
2016 American Transplant Congress
A Retrospective Analysis of Rabbit Antithymocyte Globulin Dosing, MELD, Race, and Weight on Infection and Rejection Rates in Liver Transplantation.
R. Imai, U. Wang.
Department of Pharmacy, Stanford Health Care, Stanford, CA.
INTRODUCTION: Rabbit antithymocyte globulin (rATG) use in liver transplantation is uncommon. At our center, induction therapy is comprised of rATG dosed at 1 – 2…
2016 American Transplant Congress
Ideal Outcome After Liver Transplantation: An Exploratory Study Using Machine Learning Analyses to Leverage Long-Term Registry Data from Studies in Pediatric Liver Transplantation (SPLIT).
E. Hsu,¹ M. Shaffer,^1,2 R. Anand,³ V. Ng,⁴ J. Bucuvalas.⁵
¹University of Washington School of Medicine, Seattle, WA; ²Children's Core for Biomedical Statistics, Center for Clinical and Translational Research, Seattle Children's Hospital, Seattle, WA; ³The EMMES Corporation, Rockville, MD; ⁴The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada; ⁵Cincinnati Children's Hospital and Medical Center, Cincinnati, OH.
We analyzed the Studies in Pediatric Liver Transplantation (SPLIT) registry dataset using heat map and random forests analyses (RFA) to determine if ideal outcome (IO)…